Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Contributed by: ACCESS Newswire

Tags

Healthcare & Pharmaceutical
OTCQB:SKVI
Skinvisible, Inc.
Product Announcements

More Like This

PR Newswire associated0

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

BioLife offers a new solution for oral GLP-1 delivery

BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology

PR Newswire associated0

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy

Business Wire logo

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

First product based on LTS Sorrel™ wearable drug delivery platform launched in the US

PR Newswire associated0

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform